Vimarsana
Biggest News Aggregation in the World

Jerome Solassol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jerome Solassol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jerome Solassol Today - Breaking & Trending Today

Clovis Oncology, Inc.: Clovis Oncology's Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups - Vimarsana News

Clovis Oncology, Inc.: Clovis Oncology's Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Published: September 11, 2022

Subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented in a Mini Oral session at the ESMO Congress 2022 Results reinforce potential

Source: finanznachrichten.de
Related Topics:
United StatesFrance GeneralUnited KingdomNorthern IrelandCity OfGreat BritainRebeccas KristeleitPatrickj MahaffyAnna SussmanJake DavisJerome SolassolLisa GuitermanBreanna BurkartClovis Oncology IncNational Cancer InstituteEuropean Network Of Gynaecological Oncological TrialEuropean Society Of Medical OncologyNational Cancer Research InstituteGynecologic Oncology GroupExchange CommissionMethod Of AdministrationEuropean UnionAmerican Cancer SocietyMini OralCancer Research Institute
Clovis Oncology, Inc.: Clovis Oncology's Rubraca (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial - Vimarsana News

Clovis Oncology, Inc.: Clovis Oncology's Rubraca (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial

Published: March 31, 2022

ATHENA study evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive

Source: finanznachrichten.de
Related Topics:
United StatesUniversity Of ArizonaUnited KingdomNorthern IrelandCity OfGreat BritainRebeccas KristeleitPatrickj MahaffyAnna SussmanJake DavisJerome SolassolLisa GuitermanBreanna BurkartClovis Oncology IncNational Cancer InstituteEuropean Network Of Gynaecological Oncological TrialNational Cancer Research InstituteGynecologic Oncology GroupExchange CommissionMethod Of AdministrationCreighton University School Of MedicineEuropean UnionUniversity Of Arizona College MedicineHonorhealth Research InstituteAmerican Cancer Society